These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 16483687

  • 1. A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer.
    Inoue A, Usui K, Ishimoto O, Matsubara N, Tanaka M, Kanbe M, Gomi K, Koinumaru S, Saijo Y, Nukiwa T.
    Lung Cancer; 2006 Apr; 52(1):83-7. PubMed ID: 16483687
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
    Nakadate M, Yamazaki K, Konishi J, Kinoshita I, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M.
    Anticancer Res; 2006 Apr; 26(5B):3767-72. PubMed ID: 17094399
    [Abstract] [Full Text] [Related]

  • 6. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA, Garfield DH, Khan MM, Look RM, Boehm KA, Asmar L.
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
    Fabi A, Barduagni M, Ferraresi V, Cortesi E, Gamucci T, De Marinis F, Saltarelli R, Gabriele A, Pellicciotta M, Ceribelli A, De Marco S, Facciolo F, Cognetti F.
    J Exp Clin Cancer Res; 2004 Mar; 23(1):25-32. PubMed ID: 15149147
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ, Belani CP.
    Cancer; 2008 Aug 01; 113(3):542-6. PubMed ID: 18512224
    [Abstract] [Full Text] [Related]

  • 11. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001 Aug 01; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 12. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA.
    Cancer; 2003 Aug 15; 98(4):779-88. PubMed ID: 12910523
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
    Ichiki M, Kawasaki M, Takayama K, Ninomiya K, Kuba M, Iwami F, Miyazaki N, Oishi K, Takeo S, Aizawa H, Nakanishi Y.
    Cancer Chemother Pharmacol; 2006 Sep 15; 58(3):368-73. PubMed ID: 16395589
    [Abstract] [Full Text] [Related]

  • 15. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS.
    Cancer; 2002 Sep 15; 95(6):1265-73. PubMed ID: 12216094
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A.
    Lung Cancer; 2007 Nov 15; 58(2):238-45. PubMed ID: 17658655
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.
    Yoh K, Kubota K, Kakinuma R, Ohmatsu H, Goto K, Niho S, Saijo N, Nishiwaki Y.
    Lung Cancer; 2007 Oct 15; 58(1):73-9. PubMed ID: 17548127
    [Abstract] [Full Text] [Related]

  • 19. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH.
    Clin Cancer Res; 2003 Sep 15; 9(11):4108-15. PubMed ID: 14519633
    [Abstract] [Full Text] [Related]

  • 20. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study.
    Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S, Wiesenfeld M, Jett JR.
    Am J Clin Oncol; 2003 Oct 15; 26(5):441-7. PubMed ID: 14528068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.